Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Last rites for the first glitazone

Executive Summary

FDA withdraws approval for NDA for Pfizer's Rezulin (troglitazone), a notice in the Jan. 10 Federal Register states. Pfizer withdrew the NDA for the diabetes drug after the product was pulled from the market in 2000 following 90 cases of acute liver damage, including 63 deaths (1"The Pink Sheet" March 27, 2000, p. 4)...

You may also be interested in...

AstraZeneca Exanta Risk Plan Not Sufficient To Allay Liver Toxicity Concerns

AstraZeneca's proposed Exanta risk management plan is not sufficient to alleviate liver toxicity concerns with the anticoagulant, FDA's Cardiovascular & Renal Drugs Advisory Committee said

Avandia, Actos To Accelerate Market Growth With Rezulin's Withdrawal

The removal of Warner-Lambert's Rezulin will boost sales of the two newer antidiabetic "glitazones," SmithKline Beecham/Bristol-Myers Squibb's Avandia and Lilly/Takeda's Actos.

Merck KGaA's Diversified Business Model Proves Its Worth During Pandemic

Germany’s Merck KGaA rapidly expanded its life sciences services business to support the manufacture of COVID-19 vaccines during 2020, and also expects cancer and multiple sclerosis products to fuel its sales growth in coming years.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts